PFNX News and Press, Pfenex Inc. From 05/30/19

SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for PF708 (teriparatide).  The product is propo...

The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...

Using the 351(k) and the 505(b)(2) pathways, Pfenex (PFNX) develops biosimilars of major drugs that are going off-patent. It is currently developing biosims for four major drugs, Forteo, Lucentis, Neulasta, and Oncaspar, which together have worldwide sales reaching almost $10bn. Last year, its...

Pfenex, Inc. (PFNX) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Eef Schimmelpennink – Chief Executive Officer Susan Knudson – Chief Financial Officer Conference Call Participants Jason Butler – JMP Securities Andy Hsieh ...

Pfenex (NYSEMKT: PFNX ): Q1 GAAP EPS of -$0.12 beats by $0.15 . More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology ® to develop and improve protein therapies for unmet patient needs. Using t...

SAN DIEGO, April 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced that ...

SAN DIEGO, April 23, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced the appointment of Robert Peach, Ph.D. to the Pfenex Scientific Advisory Board. “We are very excited to have Dr. Peach join our Scientific Advisory Board and look forward to his insigh...

SAN DIEGO, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, today announce...

SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that ...